Australia Set To Approve Alexion’s Soliris For PBS Coverage
This article was originally published in PharmAsia News
Executive Summary
Australia's Phamaceutical Benefits Advisory Scheme has recommended coverage of Soliris (eculizumab) for treating a rare blood disorder, with a final decision expected in November